Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An update from AC Immune SA ( (ACIU) ) is now available.
AC Immune has convened its 2026 Annual General Meeting for June 11, 2026, publishing the invitation and proxy materials and asking shareholders to vote on 2025 financial statements, compensation resolutions, director re-elections and amendments to its articles of association. The meeting follows a 2025 strategic review that cut the workforce by 30% and extended the cash runway into the fourth quarter of 2027, while advancing multiple late-preclinical and clinical programs in neurodegenerative diseases.
On May 12, 2026, the Board appointed Chair Martin Zügel as Interim CEO, effective at the AGM, when long-serving CEO Andrea Pfeifer will retire after 23 years but remain in advisory roles. To preserve governance balance, Zügel resigned from key board committees, economist Monika Bütler was named Lead Independent Director, and Carl June joined the Audit & Finance Committee on May 12, 2026, moves that aim to maintain oversight continuity as AC Immune navigates leadership transition and seeks to unlock value from its NDD-focused pipeline.
The most recent analyst rating on (ACIU) stock is a Buy with a $12.00 price target. To see the full list of analyst forecasts on AC Immune SA stock, see the ACIU Stock Forecast page.
Spark’s Take on ACIU Stock
According to Spark, TipRanks’ AI Analyst, ACIU is a Neutral.
The score is held back primarily by ongoing unprofitability and the 2025 shift back to significant cash burn alongside declining revenue and erosion of equity, despite the offsetting benefit of low leverage. Technically, the stock sits slightly above key moving averages but lacks positive momentum (negative MACD and sub-50 RSI). Valuation support is limited given the negative P/E and no dividend yield.
To see Spark’s full report on ACIU stock, click here.
More about AC Immune SA
AC Immune SA is a Swiss biopharmaceutical company focused on precision prevention and treatment of neurodegenerative diseases, including Alzheimer’s and Parkinson’s. Its pipeline centers on active immunotherapies targeting Abeta, Tau and alpha-synuclein, alongside Morphomer-based small molecule drugs and PET imaging diagnostics, often developed through partnerships with pharma groups such as Janssen, Takeda and Eli Lilly.
Average Trading Volume: 290,249
Technical Sentiment Signal: Sell
Current Market Cap: $285M
See more data about ACIU stock on TipRanks’ Stock Analysis page.